This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haiman, C. A. Articles by Henderson, B. E. Search for Related Content PubMed PubMed Citation Articles by Haiman, C. A. Articles by Henderson, B. E.

A Variant in the Cytochrome P450 Oxidoreductase Gene Is Associated with Breast Cancer Risk in African Americans

Departments of ¹ Preventive Medicine and ² Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California; ³ Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii; ⁴ Northern California Cancer Center, Fremont, California; and ⁵ Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California

Requests for reprints: Christopher Haiman, University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089. Phone: 323-865-0429; Fax: 323-865-0127; E-mail: haiman{at}usc.edu.

Variation in the cytochrome P450 oxidoreductase (POR) gene, a key regulator of type II cytochrome P450 enzymes, may affect exposure to endogenous steroid hormones and breast cancer risk. We sequenced the POR locus and tested candidate polymorphisms G5G and A503V for association with breast cancer risk among women in the Multiethnic Cohort Study (1,615 cases and 1,962 controls). The single nucleotide polymorphism (SNP) A503V was common in all racial/ethnic populations (minor allele frequency, 0.05) but was not associated with risk. SNP G5G (A G nucleotide change), which lies in a suggestive exonic splicing enhancer motif in exon 1, was common only in African Americans (minor allele frequency, 0.21) and the homozygous state was modestly associated with increased breast risk among all cases [345 cases and 426 controls; odds ratio (OR), 1.64; 95% confidence interval (CI), 0.89–3.04; P = 0.12] and among cases with advanced disease (95 cases: OR, 3.08; 95% CI, 1.42–6.70; P = 0.005). In an attempt to replicate this association, we genotyped SNP G5G in additional African American case-control studies (747 cases and 468 controls). Nonsignificant positive associations were noted with the GG genotype class in all studies. In the pooled analysis (1,038 cases and 877 controls with genotype data), the association was statistically significant among all cases (OR, 1.58; 95% CI, 1.04–2.41; P = 0.03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56–4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk. [Cancer Res 2007;67(8):3565–8]

This article has been cited by other articles:

				M. S. Udler, K. B. Meyer, K. A. Pooley, E. Karlins, J. P. Struewing, J. Zhang, D. R. Doody, S. MacArthur, J. Tyrer, P. D. Pharoah, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation Hum. Mol. Genet., May 1, 2009; 18(9): 1692 - 1703. [Abstract] [Full Text] [PDF]

				L. M. Dong, J. D. Potter, E. White, C. M. Ulrich, L. R. Cardon, and U. Peters Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes JAMA, May 28, 2008; 299(20): 2423 - 2436. [Abstract] [Full Text] [PDF]

				N. Huang, V. Agrawal, K. M. Giacomini, and W. L. Miller Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations PNAS, February 5, 2008; 105(5): 1733 - 1738. [Abstract] [Full Text] [PDF]

				A. V. Pandey, P. Kempna, G. Hofer, P. E. Mullis, and C. E. Fluck Modulation of Human CYP19A1 Activity by Mutant NADPH P450 Oxidoreductase Mol. Endocrinol., October 1, 2007; 21(10): 2579 - 2595. [Abstract] [Full Text] [PDF]